Whitehawk Therapeutics, Inc. (WHWK)

Market Cap	87.62M
Revenue (ttm)	27.78M
Net Income (ttm)	27.61M
Shares Out	47.11M
EPS (ttm)	0.91
PE Ratio	2.03
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	43,110
Open	1.895
Previous Close	1.870
Day's Range	1.860 - 1.990
52-Week Range	1.210 - 3.812
Beta	0.59
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 15, 2025

About WHWK

Whitehawk Therapeutics, Inc., an oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides a three-asset antibody-drug conjugate (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in March 2025. Whitehawk Therapeutics, Inc. was incorporated in 2007 and is headquartered in Morristown, New Jersey.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 40
• Stock Exchange: NASDAQ
• Ticker Symbol: WHWK
• Website: https://ir.whitehawktx.com

Financial Performance

In 2024, Whitehawk Therapeutics's revenue was $25.98 million, an increase of 6.69% compared to the previous year's $24.35 million. Losses were -$63.69 million, -3.15% less than in 2023.